S R Shunmugam1, Conn Sugihara2, Nick Freemantle3, Patrick Round4, Steve Furniss2, Neil Sulke2. 1. Cardiology Research Department, Eastbourne District General Hospital, East Sussex Healthcare NHS Trust, Kings Drive, East Sussex, BN21 2UD, UK. r.shunmugam@nhs.net. 2. Cardiology Research Department, Eastbourne District General Hospital, East Sussex Healthcare NHS Trust, Kings Drive, East Sussex, BN21 2UD, UK. 3. Department of Primary Care and Population Health, University College London, London, UK. 4. Xention Limited, Cambridge, UK.
Abstract
PURPOSE: The ultrarapid delayed rectifier current (IKur) carried by Kv1.5 channels, which are solely expressed in the atrium, is a potential target for safer treatment of paroxysmal atrial fibrillation (PAF). XEN-D0103 is a nanomolar ion channel blocker that selectively inhibits potassium ion flux through the Kv1.5 ion channel. The efficacy of XEN-D0103 in reducing AF burden was assessed in patients with DDDRp permanent pacemakers (PPMs) and PAF. METHODS: A double-blind, placebo-controlled, cross-over study was performed in patients with PAF and DDDRp PPMs with advanced atrial and ventricular Holters allowing beat-to-beat arrhythmia follow-up. All anti-arrhythmic drugs were withdrawn before randomised treatment. After baseline assessment, patients were randomly assigned to two treatment periods of placebo then XEN-D0103 50 mg bd, or XEN-D0103 50 mg bd then placebo. RESULTS:Fifty-four patients were screened and 21 patients were eligible and included in the randomised trial. All 21 patients completed both treatment periods. The primary endpoint was change in AF burden assessed by PPM. There was no significant difference in AF burden on treatment with XEN-D0103 versus placebo. There was a reduction in the mean frequency of AF episodes (relative reduction 0.72, 95% CI 0.66 to 0.77; p < 0.0001). XEN-D0103 was safe and well tolerated, and there were no serious adverse events. XEN-D0103 did not have any apparent effect on heart rate compared to placebo. CONCLUSIONS:XEN-D0103 did not reduce AF burden in patients with PAF and dual chamber pacemakers providing beat-to-beat monitoring. XEN-D0103 was well tolerated and did not have any apparent effect on heart rate. Although single-ion channel blockade with XEN-D0103 did not affect AF in this study, there might be a potential for this agent to be used in combination with other atrially specific drugs in the treatment of AF. EUDRACT TRIAL REGISTRATION NUMBER: 2013-004456-38.
RCT Entities:
PURPOSE: The ultrarapid delayed rectifier current (IKur) carried by Kv1.5 channels, which are solely expressed in the atrium, is a potential target for safer treatment of paroxysmal atrial fibrillation (PAF). XEN-D0103 is a nanomolar ion channel blocker that selectively inhibits potassium ion flux through the Kv1.5 ion channel. The efficacy of XEN-D0103 in reducing AF burden was assessed in patients with DDDRp permanent pacemakers (PPMs) and PAF. METHODS: A double-blind, placebo-controlled, cross-over study was performed in patients with PAF and DDDRp PPMs with advanced atrial and ventricular Holters allowing beat-to-beat arrhythmia follow-up. All anti-arrhythmic drugs were withdrawn before randomised treatment. After baseline assessment, patients were randomly assigned to two treatment periods of placebo then XEN-D0103 50 mg bd, or XEN-D0103 50 mg bd then placebo. RESULTS: Fifty-four patients were screened and 21 patients were eligible and included in the randomised trial. All 21 patients completed both treatment periods. The primary endpoint was change in AF burden assessed by PPM. There was no significant difference in AF burden on treatment with XEN-D0103 versus placebo. There was a reduction in the mean frequency of AF episodes (relative reduction 0.72, 95% CI 0.66 to 0.77; p < 0.0001). XEN-D0103 was safe and well tolerated, and there were no serious adverse events. XEN-D0103 did not have any apparent effect on heart rate compared to placebo. CONCLUSIONS:XEN-D0103 did not reduce AF burden in patients with PAF and dual chamber pacemakers providing beat-to-beat monitoring. XEN-D0103 was well tolerated and did not have any apparent effect on heart rate. Although single-ion channel blockade with XEN-D0103 did not affect AF in this study, there might be a potential for this agent to be used in combination with other atrially specific drugs in the treatment of AF. EUDRACT TRIAL REGISTRATION NUMBER: 2013-004456-38.
Entities:
Keywords:
Dual chamber pacemakers; I Kur channel blocker; Paroxysmal AF
Authors: Christian Torp-Pedersen; Dimitar H Raev; Garth Dickinson; Noam N Butterfield; Brian Mangal; Gregory N Beatch Journal: Circ Arrhythm Electrophysiol Date: 2011-08-14
Authors: T Christ; E Wettwer; N Voigt; O Hála; S Radicke; K Matschke; A Várro; D Dobrev; U Ravens Journal: Br J Pharmacol Date: 2008-06-09 Impact factor: 8.739
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; James B Seward; Toshiji Iwasaka; Teresa S M Tsang Journal: Am J Med Date: 2007-04 Impact factor: 4.965
Authors: Luis Á Pérula-de-Torres; Miguel Á Martínez-Adell; Virginia González-Blanco; José M Baena-Díez; Enrique Martín-Rioboó; Juan M Parras-Rejano; Jesús González-Lama; Remedios Martín-Alvarez; Roger Ruiz-Moral; José Á Fernández-García; Modesto Pérez-Díaz; Joaquin Ruiz-de-Castroviejo; Carlos Pérula-de-Torres; Antonio Valero-Martín; Ana Roldán-Villalobos; Margarita Criado-Larumbe; Emili Burdoy-Joaquín; Montserrat Coma-Solé; Mercè Cervera-León; Lluís Cuixart-Costa Journal: BMC Fam Pract Date: 2012-10-30 Impact factor: 2.497
Authors: Haibo Ni; Alex Fogli Iseppe; Wayne R Giles; Sanjiv M Narayan; Henggui Zhang; Andrew G Edwards; Stefano Morotti; Eleonora Grandi Journal: Br J Pharmacol Date: 2020-08-09 Impact factor: 8.739
Authors: Márcia Vagos; Ilsbeth G M van Herck; Joakim Sundnes; Hermenegild J Arevalo; Andrew G Edwards; Jussi T Koivumäki Journal: Front Physiol Date: 2018-09-04 Impact factor: 4.566
Authors: Jordi Heijman; Henry Sutanto; Harry J G M Crijns; Stanley Nattel; Natalia A Trayanova Journal: Cardiovasc Res Date: 2021-06-16 Impact factor: 10.787